Gain Therapeutics Advances GT-02287 in Parkinson’s Trials

Gain Therapeutics ( (GANX) ) has shared an announcement.

On February 6, 2025, Gain Therapeutics announced the advancement of their clinical development for GT-02287, a promising therapy for Parkinson’s disease. Following a successful Phase 1 study, they have begun a Phase 1b trial in Australia, aiming to demonstrate its disease-modifying effects. The company plans to continue its research and potentially expand trials, leveraging positive feedback from the FDA and maintaining strong financial health to support operations.

More about Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the development of next-generation allosteric therapies, with a lead drug candidate, GT-02287, targeting Parkinson’s disease. The company’s unique approach utilizes the Magellan™ platform to discover novel small molecule modulators for neurodegenerative diseases, rare genetic disorders, and oncology.

YTD Price Performance: 5.17%

Average Trading Volume: 229,570

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $64.72M

Find detailed analytics on GANX stock on TipRanks’ Stock Analysis page.